Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

122.90 +4.73 (+4.00%)
Streaming Delayed Price Updated: 11:54 AM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
51 52 Next >
BMO Capital Upgrades Biogen: Here's What You Need To Know
BMO Capital upgraded its rating of Biogen (NASDAQ:BIIB) to Outperform with a price target of $360.00, changing its price target from $217.00 to $360.00. Shares of Biogen are trading up 37.95% over the... 
Via Benzinga
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital... 
Via Benzinga
Why Acumen Pharmaceuticals Stock Is Soaring Today
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink: 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target. 
Via InvestorPlace
Why Is Biogen (BIIB) Stock Up 40% Today?
Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors. 
Via InvestorPlace
14 Analysts Have This to Say About Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: 
Via Benzinga
Biogen Settles For $900M In Bribe Case For Prescribing Multiple Sclerosis Drugs
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022
Upgrades 
Via Benzinga
These Analysts Boost Price Targets On Biogen Following Positive Alzheimer's Drug Data, Shares Jump
Biogen, Inc. (NASDAQ: BIIB) shares jumped sharply on Wednesday. 
Via Benzinga
Biogen Explodes Higher After Alzheimer's Drug Succeeds In Final-Phase Test
The drug not only removed beta amyloid, but led to a cognitive benefit. 
Via Investor's Business Daily
Netflix To Rally Around 24%? Here Are 5 Other Price Target Changes For Wednesday
Atlantic Equities raised Netflix, Inc. (NASDAQ: NFLX) price target from $211 to $283. Atlantic Equities analyst Hamilton Faber also upgraded the stock from Neutral to Overweight. Netflix shares rose... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28
Bloomberg 
Via Benzinga
What In The World Is Going On With Biogen (BIIB) Shares?
Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
Why Cassava Sciences Shares Are Soaring Higher
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading higher by 7.15 to $49.48 during Wednesday's pre-market session after Biogen Inc (NASDAQ: BIIB) and Eisai Co. 
Via Benzinga
What's Going On With Eli Lilly Stock Shooting Higher Today
Eli Lilly And Co (NYSE: LLY) shares are trading higher by 7.60% to $334.75 during Wednesday's pre-market session after Biogen Inc (NASDAQ: BIIB) and Eisai Co. 
Via Benzinga
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. 
Via Benzinga
Nasdaq Futures Slip But S&P 500, Dow Futures Hold Up Ahead Of Market Open — Apple, Biogen Stocks In Focus
U.S. stocks could struggle for direction on Wednesday after the market struggled en route to a mixed close in the previous session. Volatility could be the order of the day as another batch of Fed... 
Via Benzinga
Why Biogen Stock Is Up 40% Today
Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday. 
Via Benzinga
Biogen, Eli Lilly And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks moving higher in today’s pre-market trading session. 
Via Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. 
Via Benzinga
US Stock Futures Down Ahead Of Fed Speakers, Economic Data
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh... 
Via Benzinga
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. 
Via Benzinga
Check Out What Whales Are Doing With BIIB
A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 19 strange trades. 
Via Benzinga
Elon Musk Twitter Case Deposition Delayed, FTX US Goes Shopping, Spotify's Analyst Sees Audiobooks Immaterial: Top Financial Media Stories Tuesday, Sept. 27
Bloomberg 
Via Benzinga
The 'Transformative' Eli Lilly Drug That Could Top $25 Billion In Annual Sales
The drug already has one FDA approval as Lilly angles for a second. 
Via Investor's Business Daily
Novavax Price Target Cut By Around 80%, Plus This Analyst Predicts $129 For NIKE
Morgan Stanley cut the price target for NIKE, Inc. (NYSE: NKE) from $149 to $129. NIKE shares fell 0.6% to $99.20 on Thursday. 
Via Benzinga
Longer-Term Use, Early Initiation of Biogen's Experimental Drug For Inherited Rare Disease Slows Disease Progression
Via Benzinga
Looking At Biogen's Recent Whale Trades
Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.